---
affiliation:
- id: 0
  organization: Janssen-Cilag Oy, Vaisalantie 2, 02130, Espoo, Finland
article:
  elocation-id: another-3r-rule
  volume: 2
author:
- Annika Hulten
- Saara Rannanpää
bibliography: /tmp/tmp-60GAUWbfZZuDIj.json
copyright:
  link: "https://creativecommons.org/licenses/by-sa/4.0/"
  text: Creative Commons Attribution-ShareAlike 4.0 International
    License
  type: CC-BY-SA
csl: /app/dist/server/server/utils/citations/citeStyles/elife.csl
date:
  day: 19
  month: 01
  year: 2021
journal:
  eissn: 2670-3815
  publisher-name: Publishers of Trial and Error
  title: Journal for Reproducibility in Neuroscience
link-citations: true
title: "We need another 3R rule: repeat, repeat, repeat!"
uri: "https://jrn.trialanderror.org/pub/another-3r-rule"
---

# **Abstract**

There is consensus within the scientific community that replication
studies are scientifically sound and bring added value and reliability
to any discovery. It is also widely acknowledged that replications are
not as common as they perhaps should be. The reasons for this vary
depending on the stakeholder - here we will discuss the matter from the
perspective of the pharmaceutical industry. However, the views expressed
here are our own and do not represent the official standpoint of our
employer or the industry in general. We will focus this commentary on
the issues related to replications of the clinical part of the drug
development, as our expertise is most closely related to this area, but
the matter is equally relevant and important in the pre-clinical domain.

![](https://assets.pubpub.org/r7s03hja/image-31691157741605.png){#ni5w0x7b88w}

![](https://assets.pubpub.org/pzrlppew/image-71691160815460.png){#nrbree3j3bo}
